Advances in prostate-specific membrane antigen targeted therapies for prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 547-551, 2010.
Article
Dans Chinois
| WPRIM
| ID: wpr-252785
ABSTRACT
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein, specifically expressed in prostatic epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies for prostate cancer, including immunotherapy, radioimmunotherapy, chemotherapy and gene therapy, and initiated the clinical trials of the first-generation products. However, general clinical application of these therapies still requires extensive clinical studies to test their clinical safety, stability and efficacy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs de la prostate
/
Thérapeutique
/
Thérapie génétique
/
Radioimmunothérapie
/
Glutamate carboxypeptidase II
/
Traitement médicamenteux
/
Immunothérapie
/
Antigènes de surface
Limites du sujet:
Humains
/
Mâle
langue:
Chinois
Texte intégral:
National Journal of Andrology
Année:
2010
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS